Register
Login:
Share:
Email Facebook Twitter




Add Plethora to quick picks

Plethora Share Price (PLE)



Share Price Information for Plethora (PLE)


Share Price: 3.625Bid: 3.50Ask: 3.75Change: 0.00 (0.00%)No Movement on Plethora
Spread: 0.25Spread as %: 7.14%Open: 3.625High: 3.625Low: 3.625Yesterday’s Close: 3.625

Plethora Solutions Holdings Plc Ord 1P

Plethora is listed in the FTSE AIM All-Share
Plethora is part of the Pharmaceuticals & Biotechnology sector






Share Price SpacerPrice
3.625

Share Price SpacerBid
3.50

Share Price SpacerAsk
3.75

Share Price SpacerChange
0%0.00

Share Price SpacerVolume
144,671

Share Price SpacerOpen
3.625

Share Price SpacerHigh
3.625

Share Price SpacerLow
3.625

Share Price SpacerClose
3.625

Share Price SpacerCurrency
GBX


Currency Issue Country Shares in Issue Market Capitalisation Market Size
GBX GB 823.30m £29.84m 50,000

52 Week High 11.88 52 Week High Date 16-SEP-2014
52 Week Low 3.38 52 Week Low Date 13-AUG-2015

# Trades Vol. Sold Vol. Bought PE Ratio Earnings Dividend Yield
5 5,878 125,000 -1.128 -3.22 0.00 0.00




Date
Time
Trade Prc
Volume
Buy/Sell
Bid
Ask
Value
 

28-Aug-15
16:29:46
3.7499
25,000
Buy* 
3.50
3.75
937.48
Trade Type:
Ordinary

28-Aug-15
16:29:31
3.7225
50,000
Buy* 
3.50
3.75
1,861
Trade Type:
Ordinary

28-Aug-15
16:22:09
3.68
50,000
Buy* 
3.50
3.75
1,840
Trade Type:
Ordinary


*Buys and Sells are calculated on the difference between the trade price and the current mid price. As such, they can occasionally be incorrect.

View more Plethora trades >>

Directors Deals for Plethora (PLE)
Trade DateActionNotifierPriceCurrencyAmountHolding
01-Apr-15Notification of Holding
Trade Notifier Information for Plethora Solutions Holdings
James (Jim) Mellon held the position of Chairman at Plethora Solutions Holdings at the time of this trade.
 James (Jim) Mellon
00246613861
29-Jan-15Notification of Holding
Trade Notifier Information for Plethora Solutions Holdings
James (Jim) Mellon held the position of Chairman at Plethora Solutions Holdings at the time of this trade.
 James (Jim) Mellon
00145974014
12-Sep-13Notification of Holding
Trade Notifier Information for Plethora Solutions Holdings
Mike Collis held the position of Non-Executive Director at Plethora Solutions Holdings at the time of this trade.
 Mike Collis
006419200
View more Plethora directors dealings >>

Date/Time
Author
Subject
Share Price
Opinion
Today 10:02
ProfessorZ
I cannot argue
3.63
No Opinion

Everything written is fundamentally solid, yet the pessimistic views are either based upon historic events or simply discount major factors such as the exising patent and the sums invested by parties with an interest in making this successful. I am not suggesting for a second that this will not slip further, indeed any fear of a cash-call will do little to elevate the current price, however even after going back to shareholders, the potential is huge. I remember asking Jamie about the delay and he responded to me at the time that they planned to release with the 6 dose canister. There was a risk that the reapproval could necessitate the interim solution, but my reading of today's news is certainly not something that gives me cause for concern.
Fri 23:30
ProfessorZ
I cannot argue
3.63
No Opinion

Everything written is fundamentally solid, yet the pessimistic views are either based upon historic events or simply discount major factors such as the exising patent and the sums invested by parties with an interest in making this successful. I am not suggesting for a second that this will not slip further, indeed any fear of a cash-call will do little to elevate the current price, however even after going back to shareholders, the potential is huge. I remember asking Jamie about the delay and he responded to me at the time that they planned to release with the 6 dose canister. There was a risk that the reapproval could necessitate the interim solution, but my reading of today's news is certainly not something that gives me cause for concern.
Fri 22:36
StoneyD
RE: I WONDER HOW...
3.63
No Opinion

They are saying once again that "we are making good progress and its all going to plan" In fact it isnt going to plan, they are now two years late in marketing the product which originally was March 2015 for FDA approval if my memory serves me right. They do not state what progress has been made and obviously are in trouble. I had invested heavily here but am now out at a big loss, IMO the only time to put cash into PLE is when they can actually say that they have a proved and successful delivery system for Fortacin which ticks all the boxes, otherwise it's a very long haul with the sp drifting down with limited news. Dont hold your breath folks and GLA
Fri 22:00
Alquemie
RE: I WONDER HOW...
3.63
No Opinion

Thank you, JW. It's a minimum nine months: six months for stability, 60 day for variation review, plus a month for fill, equlibration and paper work. According to the RNS, earliest GMP fill will be December, so September (pehaps fad end of August) 2016 approval. If successful, allowing for commercial product supply, product launch is more likely to be early 2017.
Fri 21:36
JWilliams1989
RE: I WONDER HOW...
3.63
No Opinion

Excellent post as always. Is 7 months not enough for a variation?
Fri 21:07
Alquemie
RE: I WONDER HOW...
3.63
No Opinion

JW, the rationale for six doses was to obtain the highest price per dose while maintaining an acceptable out of pocket price per script (Fortacin is not reimbursable in Europe: the retail drug cost plus any consulting charge would be met entirely by the patient). Being non-reimbursable, Recordati could charge whatever they like, although in practice it needs to be close to the cost of existing treatments, with dapoxetine being the benchmark. Looking at the shot weights PLE are considering, I believe that the "reduced fill product" will end up delivering more than 6 doses. Volume has a negligible effect on manufacturing cost, but what it means is, rather than having to shell out, say Euro 50 per script each month, patients will only need a repeat script every two or three months. In short, a larger volume product will significantly impact revenue. Whether Recordati will swallow the revised business case (launch delay, the bother of the phony 20 canister launch and erosion of market exclusivity, lower script volumes) remains to be seen. What is clear is that there is no possibility of PLE having a "reduced fill product" approved by June 2016, which is the last trigger date for the Recordati milestone.

Share prices shown are taken at time of message posting.
Thread ViewThread View
View more share chat for Plethora (PLE) >>
Please Login or Register to post messages






Sign up for Live Prices




Home  |  Contact Us  |  About Us  |  Careers  |  Advertise with Us  |  Sitemap  |  Terms & Conditions  |  Cookies  |  Privacy


Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.